These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37162451)

  • 1. ISCOMs/MPLA-Adjuvanted SDAD Protein Nanoparticles Induce Improved Mucosal Immune Responses and Cross-Protection in Mice.
    Zhu W; Park J; Pho T; Wei L; Dong C; Kim J; Ma Y; Champion JA; Wang BZ
    Small; 2023 Aug; 19(34):e2301801. PubMed ID: 37162451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
    Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
    J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
    Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
    Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
    Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monophosphoryl Lipid A-Adjuvanted Virosomes with Ni-Chelating Lipids for Attachment of Conserved Viral Proteins as Cross-Protective Influenza Vaccine.
    Dong W; Bhide Y; Marsman S; Holtrop M; Meijerhof T; de Vries-Idema J; de Haan A; Huckriede A
    Biotechnol J; 2018 Apr; 13(4):e1700645. PubMed ID: 29278302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
    Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
    Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.
    Coulter A; Harris R; Davis R; Drane D; Cox J; Ryan D; Sutton P; Rockman S; Pearse M
    Vaccine; 2003 Feb; 21(9-10):946-9. PubMed ID: 12547607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.
    Liu H; Patil HP; de Vries-Idema J; Wilschut J; Huckriede A
    PLoS One; 2013; 8(7):e69649. PubMed ID: 23936066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunostimulating complexes (ISCOMs) for nasal vaccination.
    Hu KF; Lövgren-Bengtsson K; Morein B
    Adv Drug Deliv Rev; 2001 Sep; 51(1-3):149-59. PubMed ID: 11516786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Sequential Immunization Using Salmonella Oral Administration Followed by an Intranasal Boost with Ferritin-Based Nanoparticles Enhanced the Humoral Immune Response against H1N1 Influenza Virus.
    Wang Z; Zhang T; Jia F; Ge C; He Y; Tian Y; Wang W; Yang G; Huang H; Wang J; Shi C; Yang W; Cao X; Zeng Y; Wang N; Qian A; Wang C; Jiang Y
    Microbiol Spectr; 2023 Jun; 11(3):e0010223. PubMed ID: 37154735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monophosphoryl lipid A-adjuvanted nucleoprotein-neuraminidase nanoparticles improve immune protection against divergent influenza viruses.
    Wang Y; Dong C; Ma Y; Zhu W; Gill HS; Denning TL; Kang SM; Wang BZ
    Nanomedicine; 2023 Jan; 47():102614. PubMed ID: 36265560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel antigen of Mycobacterium tuberculosis and MPLA adjuvant co-entrapped into PLGA:DDA hybrid nanoparticles stimulates mucosal and systemic immunity.
    Khademi F; Derakhshan M; Yousefi-Avarvand A; Najafi A; Tafaghodi M
    Microb Pathog; 2018 Dec; 125():507-513. PubMed ID: 30352265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.